Cargando…
Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate
The clinical use of amifampridine phosphate for neuromuscular junction disorders is increasing. The metabolism of amifampridine occurs via polymorphic aryl N-acetyltransferase (NAT), yet its pharmacokinetic (PK) and safety profiles, as influenced by this enzyme system, have not been investigated. Th...
Autores principales: | Haroldsen, Peter E, Garovoy, Marvin R, Musson, Donald G, Zhou, Huiyu, Tsuruda, Laurie, Hanson, Boyd, O’Neill, Charles A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317230/ https://www.ncbi.nlm.nih.gov/pubmed/25692017 http://dx.doi.org/10.1002/prp2.99 |
Ejemplares similares
-
Five years experience on 3,4-diaminopyridine phosphate in Lambert–Eaton syndrome: Case reports
por: Portaro, Simona, et al.
Publicado: (2017) -
Population Pharmacokinetics/Pharmacodynamics of 3,4‐Diaminopyridine Free Base in Patients With Lambert‐Eaton Myasthenia
por: Thakkar, Nilay, et al.
Publicado: (2017) -
Investigation of N-Acetyltransferase 2-Mediated Drug Interactions of Amifampridine: In Vitro and In Vivo Evidence of Drug Interactions with Acetaminophen
por: Park, Yeo-Dim, et al.
Publicado: (2023) -
Amifampridine for Lambert-Eaton myasthenic syndrome
Publicado: (2022) -
Amifampridine Phosphate (Firdapse) Is Effective in a Confirmatory Phase 3 Clinical Trial in LEMS
por: Shieh, Perry, et al.
Publicado: (2019)